Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Becker Muscular Dystrophy

In brief

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON and GRAND CANYON are fully enrolled.

Key facts

Study ID
NCT05291091
Run by
Edgewise Therapeutics, Inc.
People needed
244
Starts
2022-11-10
Expected to finish
2026-09-01
Last updated by the study team
2026-07-31

Who can join

Age: 12 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.